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Summary.-(A xCBA(T6))F1 mice bearing F1 mammary carcinomas for9 days were
injected i.v. with A strain spleen cells. The A spleen cells were from either non-
immune donors or mice which had received an i.p. injection of F1 tumour cells 9 days
previously, and were thus immune to the CBA component of the tumour. Fourteen
days after receiving parental spleen cells, the Fl-tumour-bearing mice were killed
and their spleen ratios and indices were determined as an index of the severity of the
graft-versus-host reaction (GvHR) induced. The spleen indices were compared with
those in non-tumour-bearing F1 mice, receiving aliquots of the same parental cell
suspensions. At the higher doses of A spleen cells, the presence of an F1 tumour
reduced the GvHR. At the same time, in3/5 experiments, the weight of the F1 tumour
in mice injected with immune A spleen cells was less than that in F1 mice receiving
the same number of tumour cells but no spleen cells. A reduction in GvHR and a
decrease in tumour weight was not seen when F1 mice carrying an A strain tumour
were injected with A strain spleen cells immune to an F1 tumour. Adding 23-day F1
tumour-bearing F1 spleen cells to A spleen cells did not reduce the GvHR induced in
further non-tumour-bearing F1 recipients by the parental cells. This was evidence
against the presence of suppressor cells in the tumour-bearing F1 spleen.
When 51Cr-labelled A strain spleen cells were injected into F1 mice, some of which
had a tumour and therefore an enlarged spleen, there was an inverse relation between
the size of the spleen and the number of parental cells therein, per g spleen 4 h after
injection.
It is thus suggested that the reduction in GvHR in Fl-tumour-bearing F1 mice,
after injection of parental spleen cells, is due first to a reduction in the concentration
of donor cells in the recipient spleen (i.e. the same number of donor cells in a larger
spleen) and second to pre-occupation of the donor cells in reacting to the tumour.
THERE HAVE BEEN a number of reports
that injection ofparental immunologically
competent cells (ICC) into F1 hybrid mice
will inhibit the growth of tumours trans-
planted to these animals. There are two
categories of this phenomenon, depending
on whether the ICC are injected before or
after tumour transplantation. Wigzell
(1961) found that in 3 different F1 hybrids,
growth of a parental lymphoma was re-
tarded by giving ICC from the other
parent 5 days before the tumour, if the
ICC were non-immune, or on the same day
ifthe cells were tumour-immune. A similar
result was obtained by Osborne & Katz
(1977) using a plasmacytoma. However,
in their experiment, parental ICC isogenic
with the tumour also retarded tumour
growth, though to a lesser extent than
ICC from the other parent. Rumma et al.
(1977) also found that ICC from the same
parent as the tumour could inhibit the
growth of this carcinoma in F1 rats, if
injected concurrently with the tumour
cells or 7-14 days previously.
In contrast, Woodruff & Boak (1965)
reported the inhibition of tumour growth
when A strain mammary carcinomasT. WHITMARSH-EVERISS AND M. 0. SYMES
growing in (A x CBA)F1 mice were treated
by 3 injections of CBA ICC (immune to
the tumour) on Day 7, 14 and 21 after
tumour transplantation.
There are two possible mechanisms for
this effect; first, if there is a genetic differ-
ence between tumour and injected ICC,
an allograft rejection reaction against the
tumour, and second, in all cases, the
induction of a graft-vs-host reaction
(GvHR) with resultant host immuno-
potentiation (Osborne & Katz, 1977).
There is a further question raised by
these studies. Can the tumour acting as an
"antigenic mass" divert the action of the
ICC away from the host, thus protecting
the host from GvHR? We have investi-
gated this in two tumour-host systems.
First an (A x CBA)F1 tumourgrowing in an
F1 host; these hybrids received parental
ICC, which could thus, in theory, react
against both tumour and host. Second, an
A strain tumour growing in (A x CBA)F1
hosts; the injected A strain ICC could now
react only against the host. The resultant
GvHR, measured as an increase in spleen
weight, was compared between tumour-
bearing and non-tumour-bearing animals
in these two systems.
MATERIALS AND METHODS
Animals.-Highly inbred strain A/Mi and
CBA H-T6(CBA) mice were maintained in this
department by strict brother x sister mating
of litter mates. F1 animals were produced by
crossing A females with CBA males.
The F1 animals used as recipients oftumour
transplants and parental spleen cells were
aged 2-3 months.
Tumours.-Both A and F1 mice (where
the A parent is female) develop spontaneous
mammary carcinomas. These tumours may
be passaged serially in isogenic hosts.
Tumour-cell suspensions were prepared
from these tumours by the method of Milas
et al. (1974).
Transplantation of tumours.-Tumours
were transplanted by injection of a cell sus-
pension into isogenic hosts. Each recipient
received 1 or 3 x 106 viable tumour cells by
s.c. injection.
Immuni,ation of donor mice against F1
tumours.-A-strain mice aged 1-2 months
each received an i.p. injection of 195-2 x 106
tumour cells. The spleens of these mice were
harvested 9 days later. In each experiment
spleen cell donors and recipient mice were of
the same sex.
Preparation of spleen-cell suspensions.-
The spleen was excised and cut into small
pieces which were reduced to a cell suspension
by gentle grinding in a hand-operated glass-
piston blender. The viable cell count was
determined by dye exclusion using 04165%
w/v trypan blue as the leucocyte diluent in a
haemacytometer.
Spleen ratios and indices-.The spleen ratio
was defined as the wt of spleen (mg)/wt of
mouse (g). This was evaluated on Day 14
after injection of parental cells into an F1
hvbrid, as Howard (1961) had shown that in
the combination A- > (A x CBA)F1 the phago-
cytic index of the recipients, as a measure of
GvHR, is maximal at 12-16 days. It was also
demonstrated in the combination CBA or
C57 BL- > (CBA x C57 BL)F1, that spleno-
megaly and an increased phagocytic index
followed a similar time course. The spleen
index for each animal was the quotient
individual spleen ratio/mean control spleen
ratio. The denominator was the mean for
non-tumour-bearing or tumour-bearing mice
as appropriate. In most experiments, the
presence of a tumour itself induced spleno-
megaly (Woodruff & Symes, 1962) and this
had to be considered in evaluating the in-
crease in spleen weight due to the induction of
a GvHR. Sample calculations are presented
in Table I.
Irradiation of mice.-This was given using
a 4kCi 137Cs source of y-rays at an FSD of
60 cm. The dose rate was 0 9 rad/s.
51Cr labelling of spleen cells-.Spleen-cell
suspensions were prepared as described
above and the contaminating erythrocytes
were lysed using tris-buffered NH4Cl (Boyle,
1968).
The resulting cell suspension was then
labelled with 51Cr (10uCi of 51Cr as sodium
chromate/2 x 108 cells/ml).
RESULTS
The effect of an (A x CBA)F1 tumour in
reducing the GvHR induced by i.v. injection
of A strain spleen cells into (A x CBA)F1
mice
A total of 5 experiments were per-
formed. In Expt 1, increasing doses of A
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TABLE I.-The method of calculating the spleen ratio and spleen index of (A x CBA)Fl
normal and tumour-bearing mice, 14 days after they had received 108 A spleen cells i.v.
In tumour-bearing mice the weight of the tumour is subtracted from the total weight to
obtain the corrected body weight, used in the calculations
Group
(A x CBA)Fl
Wt of
mouse+
tumour
(g)
Wt of
tumour
(g)
A- (A x CBA)F1
(A x CBA)F1 with tumour
A- (A x CBA)F1 with
tumour
23-34
21-10
23 77
23 67
22-88
26 34
23 09
1-65
1 54
1 26
1 32
1-02
1-25
1 54
Wt of
mouse
(g)
23 18
23 32
24 12
22 52
22 82
24 64
22 07
26 58
etc.
21 69
19 56
22 51
22 35
21 86
25 09
21 55
etc.
Wt of
spleen
(mg)
88-1
90 5
905
86 7
92 8
93.9
171 5
214 5
181 4
229 0
196-3
147 6
138 1
243 6
241-4
Spleen ratio
(wt ofspleen/
body wt)
Individual mean
3 80I
3 88
3.73I
384 386
407
3 81
7.77
8 07
8-36'
1170
872
6 60
6 31J
9 71
11-20
Spleen index=
individul spleen
ratio
mean control
spleen ratio
2-01
2 09
8 34
1 16
1 34
TABLE II.-The spleen indices of normal and F1-tumour-bearing (A x CBA)F1 mice 14
days after receipt ofincreasing doses of non-immune or tumour-immune A spleen cells f~~~~~Ep
Dose of
A spleen
cells
x 106 i.v.
50N
100 N
Expt 1
Mean spleen index (± s.e.)
No tumour
1-49+ 0-14
2-15+0-15
Tumour
1-14+ 0-15
1-67+0-15
P*
N.S.
<0-05
Expt 2
Mean spleen index
No tumour Tumour
50Im 1-86+0-15 1-55+0-17 N.S. 1-58+0-11
00 Im 2-22 + 0-15 1-38 +0-17 < 0-001 1-94+0-11
150 Im 2-53+0-11
N=non-immune. Im =immune to F1 tumour. 5-8 animals/group.
* By analysis of variance.
spleen cells either non-immune or immune
to F1 tumour, were injected into F1
recipients. For each dose ofinjected spleen
cells, half the recipients had received 106
F1 tumour cells 9 days beforehand. All F1
mice were killed 14 days after receiving
A spleen cells, and their spleen indices
were determined.
The presence of a tumour did not
inhibit the GvHR induced by 5 x 10J non-
immune or tumour-immune A spleen cells.
However, when the spleen-cell dose was
increased to 108 cells, the spleen index of
tumour-bearing mice was significantly
lower in animals receiving either non-
immune or immune spleen cells (Table II).
p
0-87 + 0-12 < 0-001
1-30+ 0-12 < 0-001
1-82+0-12 <0-001
In Expt 2, the findings were similar, the
presence of a tumour causing a signifi-
cantly lower spleen index in F1 animals
receiving either 5, 10 or 15 x 107 tumour-
immune parental spleen cells (Table II).
TABLE III.-The spleen indices of normal
and Fl-tumour-bearing F1 mice 14 days
after receipt of 108 tumour-immune A
spleen cells i.v. (5-7 animals/group)
Mean spleen index + s.e.
Expt No tumour Tumour
3 2-12+0-08 1-33+0-07
4 231+010 1-60+009
5* 1-84+0-07 0-98+0-07
* Tumour dose 3 x 106.
p
(2-tail t test)
<0-001
<0-001
<0-001
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TABLE IV.-The spleen indices of normal and A-strain-tumour-bearing F1 mice, 14 days
after the receipt ofincreasing doses ofFl-tumour-immune A spleen cells i.v. The weight of
tumour in the groups of tumour-bearing mice receiving spleen cells is compared with the
tumour weight in uninjected mice
Expt 6 (6-8 animals/group)
C-A
Dose ofA Mean spleen index
spleen cells* A Mean tumour
( x 106 i.v.) No tumour Tumour Pt wt (g) P
0
50
100
150
1-59+0-13
2-32+0-13
2-42 + 0-12
1-53+0-13 N.S.
1-96+0-13 N.S.
2-25 + 0-12 N.S.
* Immune to F1 tumour tissue.
t By analysis ofvariance.
In Expts 3-5, only 108 tumour immune
A spleen cells were injected into either
normal or Fl-tumour-bearing F1 mice. In
each experiment the spleen index in the
tumour-bearing animals was significantly
lower (Table III) implying that the
presence of a tumour partially inhibited
the production of a GvHR.
The effect of an A strain tumour on the
GvHR induced by i.v. injection of A strain
spleen cells into (A x CBA)F1 mice
In order to study whether the reaction
ofthe injected parental spleen cells against
the F1 tumour was important in reducing
theGvHRinducedbythese cellsintumour-
bearing F1 mice, an additional experiment,
Expt 6, was performed. The F1 mice
carriedanAtumouragainstwhich A spleen
cells could not react. F1 mice received 106
tumour cells on Day 0 and 5, 10 or 15 x 107
spleen cells on Day 9. Similar doses of A
spleen cells from the same cell suspension
were injected into separate groups ofnon-
tumour-bearing F1 mice. All the A strain
donor mice had received 1-8 x 106 F1
tumour cells i.p. 9 days before harvesting
their spleens, in order to immunize
against the CBA component of the F1. All
normal and tumour-bearing F1 mice
receiving spleen cells were killed 14 days
later and their spleen indices were deter-
mined.
The presence ofa tumour did not reduce
the GvHR induced by any of the doses of
parental spleen cells injected (Table IV).
0-80 + 020
1-25 + 0-22 N.S.
1-40+ 0-22 N.S.
0 75 + 0-22 N.S.
The effect of injecting A strain spleen cells
i.v. intoF1 mice bearing eitherF1 or A strain
tumours, on tumour size
The weight of the tumour, in F1 mice,
14 days after injection of parental spleen
cells, was determined in Expts 1-6.
In 3 ofthe 5 experiments 1-5, where the
tumour was of F1 genotype, animals
receiving 108 spleen cells i.v. showed a
significantly smaller tumour than tumour-
bearing animals into which parental ICC
had not been injected (Table IV).
Injection ofA strain spleen cells into F1
mice bearing A strain tumours, did not
reduce the tumour size (Expt 6, Table IV).
Thus, in Expts 3-5, reduction in the
GvHR induced by parental spleen cells
injected into tumour-bearing F1 mice was
associated with a reduction in the size of
the F1 tumour. This suggested that the
reaction of the spleen cells against the
tumour may have contributed to a re-
duction in the GvHR induced.
The effect of admixed F1 spleen cells, from
23-day Fl-tumour-bearing F1 mice, on the
GvHR-inducing capacity of normal A
spleen cells
It seemed possible that suppressor T
cells in the spleens of Fl-tumour-bearing
mice might have contributed to the reduc-
tion in GvHR induced when these mice
received parental spleen cells. To test this
hypothesis, 3 similar experiments (7-9)
were performed, using tumour-bearing
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TABLE V.-A comparison of F1 tumour
weights at Day 23 in two groups of Fl
mice. The first group had received 106 F1
tumour cells s.c. only on Day 0, and the
second group had tumour cellsfollowed by
108 F1-tumour-immune A-strain spleen
cells i.v. on Day 9 (5-8 animals/group)
Mean tumour wt (g)
Tumour+
Expt Tumour only A spleen cells
1 2-76+0 49 2-89+0 57
2 1-36 + 0-23 1-39 + 0-23
3 0 49+0 07 0-25+0-06
4 2-05+0-42 0-58+0-42
5* 3-34 +0*35 0-91 + 0-38
p
(2-tail t test)
N.S.
N.S.
<005
< 0 05
< 0-002
* Tumour dose 3 x 106.
mice from Expts 3, 4 or 5 as donors. Fifty
million F1 spleen cells from F1 mice
carrying an F1 tumour for 23 days, were
mixed with 108 A strain spleen cells. In a
separate cell mixture, 5x 107 F1 spleen
cells from non-tumour-bearing mice were
combined with 108 A spleen cells. The
GvHR induced by these two cell mixtures,
on i.v. injection into separate groups of
normal F1 mice, was compared with that
induced by 108 A spleen cells alone,
injected i.v. into a third group of F1
animals. All F1 mice receiving spleen cells
were killed 14 days later and their spleen
indices were determined in order to assess
the magnitude of the GvHR induced.
It may be seen from Table VI that F1
spleen cells from tumour-bearing animals
did not reduce the GvHR induced by
admixed A spleen cells. Thus, no evidence
of a suppressor-cell population in the
spleens of Fl-tumour-bearing F1 mice
could be found by adoptive cell transfer.
However, it might be argued that the
intact spleen did not allow adequate
"space" for the proliferation of any
potential F1 suppressor cells. As a variant
of this experiment (Expt 10) normal F1
mice, which had received 3 Gy whole-body
irradiation 24 h before, served as recipi-
ents for the cell mixtures. As may be seen
from Table VI, when the same cell mix-
tures as were transferred into unirradiated
F1 recipients (Expt 9) were injected into
irradiated recipients (Expt 10), a reduc-
tion in GvHR was obtained, on admixture
of A spleen cells with both normal and
tumour-bearing F1 spleen cells. However,
the reduction of GvHR was not due to the
presence of suppressor cells as there was
no significant difference in spleen index
between mice receiving normal and
tumour-bearing F1 spleen. It is therefore
suggested that in the irradiated recipient
there is more space for the transferred F1
cells to proliferate, and that this com-
petition for space inhibits the multiplica-
tion ofA spleen cells and hence the degree
of GvHR induced.
The distribution of 51Cr-labelled A spleen
cells in normal and tumour-bearing F1 mice
108 A strain spleen cells (from donors
immunized 9 days before against F1
TABLE VI.-Spleen indices ofF1 mice 14 days after receiving 108 A strain spleen cells i.v.
or A cells combined with 5 x 107 F1 cells from normal or 23-day Fl-tumour-bearing F1
mice. The spleen-cell recipients in Expt 10 received 3 Gy whole-body irradiation on
Day - 1 (3-5 animals/group)
Dose ofspleen cells x 106 i.v.
, ~~~~~~~~~A
100 A+ 50 N(F1)
2-02 + 0-09
1-81 + 0 07
1-79+0-13
1-34 + 0-29
100 A+ 50 T(F1)
1-75+ 0-11
1-83 + 0-07
1-96+0-11
*1*32 +0'29
p
N(F1) vs 100 A
t-test
N.S.
N.S.
N.S.
< 0-05
* InExpt 10Pforcol 2vcol 4 <0-05.
Expt
7
8
9
10
100 A
2-12 + 0-09
1-96 + 0-07
2-06+0-11
*2-26 + 0-26
p
N(F1) vs T(F1)
t-test
N.S.
N.S.
N.S.
N.S.
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TABLE VII.-The spleen ratios of, and ct/min/y ofspleen in, F1 mice 4hafJter receiviny 1ox
51Cr-labelled, A strain spleen cells i.v. Some of the F1 recipients had received 106 tumour
cells s.c.frorn the F1 tunmours, H7 or H3, 23 days earlier. The donor spleen, cells wf-erefroml.
animals immunized against the F1 tumour H3
No. of Aleani 1' (2-tail t test) AMean ct P
obser- spleeIn
X 10 3
Tumour vations ratio vs no tumour vs H7(4) /min/g spleen vs I1) ttimnoriiI vS H7(4)
67-73+4 7
36-04 + 5-2
N.S. 46-65+4-7
< 0 001
<001
8136 + 549
7904 + 784
N.S. 8402 + 490
tumour H3*) were injected into 3 groups
of F1 mice, viz.: (1) non-tumour-bearing;
(2) bearing F1 tumour H7* for 23 days and
(3) carrying F1 tumour H3* for 23 days.
The mice were killed 4 h later and the
y ct/g/min and the total organ ct/min for
the liver and spleen of each animal were
determined.
The total liver ct/min ere similar in all
3 groups of animals, viz.: (1) 19,530 + 439
(s.e.) (2) 20,013 + 934, (3) 18,734 + 1310.
The results for the spleen are shown in
Table VII. The y ct/g/min from the spleen
were significantly reduced in mice bearing
tumour H7 or H3 compared to non-
tumour-bearing mice. The spleens of mice
bearing tumours H7 and H3 were signifi-
cantly enlarged (Table VII). Thus, there
is no significant difference in ct/min/spleen
between the 3 groups (Table VII).
Thus, it may be argued that splenic
hyperplasia developing between Days 9
and 23 after tumour transplantation, due
to the growth of the tumour, provides
competition with the donor A cells for
space within the recipient spleen. This
relationship may thus have a similar
mechanism to the reduction in GvHR
induced by A cells admixed with F1 cells
on injection into irradiated F1 mice.
Although the concentration of labelled
cells seeding into the enlarged spleens of
tumour-bearing mice is lower than in
control spleens, the total number of
labelled spleen cells seeding into each
group of spleens is approximately con-
stant. However, in the induction of a
GvHR, it may be the concentration of
dlonor ICC which determines the magni-
tude of the effect in a particuilar or gan. In
the spleen of an F1 mouise marker-
chromosome studies have shown that
after injection of par ental cells, spleno-
mnegaly on Day 14 is duie to hvperplasia of
host-type cells (Fox, 1962). This host-cell
proliferation is a reaction to damnage in-
flicted by the cytotoxic action ofthe donor
cells. It is suiggested that the magnitude of
this damage is due to the concentration of
the donor cells rather than their absolute
number.
I)ISCUSSION
Both the presence of a tuimour and a
(GvHR are able to induce splenomegaly,
and the interaction of these two factors
may arguably invalidate the use of spleen
weight as a measure of GTvHR and its
inhibition by the presence of a tumour.
We think this unlikely, as in the presence
of both an F1 hybrid tumour (Table II,
Expts and 2) and a parental t,umtour
(Table IV, Expt 6) increasing the injected
number of donor spleen cells leads to an
increase in spleen index.
Reduction in GvHR, when parenital
spleen cells are injected into a tumotir-
bearing, rather than a normal F1 host, is
associated with a reduiction in the con-
centration of donor spleen cells in the
recipient spleen. However, the concomitant
reduction in host tnumouir size (Expts 3-5)
and the dependence of the reduction in
(WvHR on the number of parental cells
injected (Expt 1), suggest that an altera-
tion in the concentration of donor spleen
* Tumouirs H7 and H3 were mammary carciinomas arising spontaneously in (A x (C13A)F1 mice. TtlimoorLs
H7 and H3 wrere respectively in their 4th aindI 18th transplant generatio'ns in isogenic hosts, when u0sed(.
Nil
H7
H3
5
4
01
5-18+0 85
10-40 + 096
826(+±085
<0-001
< 0*05
ct/mill/
Spleen
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cells is not the sole explanation for the
effect. In addition, the donor spleen cells
attack the tumour, when this constitutes
a recognizable antigenic mass (an F1
rather than an A tumour) with consequent
deflection of the immune reaction from
host to tumour.
It is possible that the different cell
populations in the spleens of normal and
tumour-bearing mice, might render the
latter animals less susceptible to induction
of GvHR. However, the spleens of both
tumour-bearing mice (Woodruff & Symes,
1962) and mice in the proliferative phase
of a GvHR (Howard, 1961) show similar
histological pictures; in both there is
proliferation of plasma cells and their
precursors in the red pulp.
Fujimoto et al. (1976) showed that the
spleens of tumour-bearing mice contained
suppressor cells, which, on adoptive trans-
fer to syngeneic tumour-immune mice,
could block tumour rejection. It was thus
possible that the parental spleen cells,
inducing GvHR, might be suppressed by
the presence of a tumour in the recipient
F1. Expts 7-9, in which spleen cells from
tumour-bearing F1 mice and A spleen cells
were mixed prior to adoptive transfer to
further normal F1 mice, failed to demon-
strate suppressor cells in the F1 mice with
tumours. The absence of suppressor cells
in those mice is also suggested by the
ability of injected A spleen cells to retard
the growth ofa tumourintheF1 recipients.
Furthermore, Rees & Symes (1971) found
no difference in the ability of A spleen
cells from normal and tumour-bearing
mice to induce GvHR on injection into F1
recipients.
Animals with an ongoing GvHR re-
tarded the growth ofa subsequently trans-
planted neoplasm. This was ascribed to
host "immunopotentiation" (Osborne &
Katz, 1977). However, such a phenomenon
is unlikely to explain the reduction in
GvHR described in the present paper, as
the GvHR was not reduced when an A
strain tumour was present in the F1
receiving A spleen cells.
The idea that a tumour may deflect the
immune response of foreign ICC to itself,
with consequent protection of the host
against GvHR may stimulate attempts to
treat neoplasms by adoptive transfer of
foreign immunologically competent cells.
We are indebted to Miss Beverley Fermor and
Miss Doris Heinemann for their technical assistance.
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